Showing 1101-1110 of 3039 results for "".
- JUVÉDERM Day Returns with Limited-Time Offers Through Rewards Programhttps://modernaesthetics.com/news/juvederm-day-returns-limited-time-offers-through-rewards-program/2482957/Members of JUVÉDERM’s Alle loyalty rewards program will have an opportunity to purchase “buy one, get one” gift cards as part of JUVÉDERM Day on August 20, according to Allergan Aesthetics, an AbbVie company. Details of the exclusive, limited limited-time offers are as follows: •
- Study: Aesthetic Surgeries Rise Among GLP-1 RA Patientshttps://modernaesthetics.com/news/study-aesthetic-surgeries-rise-among-glp-1-ra-patients/2476139/Aesthetic surgery among patients with previous glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is increasing compared with postbariatric surgery patients, according to new research published in the Aesthet
- Alma Introduces PixelPeel™ Laser Peel for Minimal-Downtime Skin Renewalhttps://modernaesthetics.com/news/alma-introduces-pixelpeel-laser-peel-for-minimal-downtime-skin-renewal/2476137/Alma has launched PixelPeel™, a new fractional laser peel treatment designed for subtle, controlled skin resurfacing with minimal recovery time. The treatment is compatible with the Alma Pixel™ and Alma Hybrid® platforms and uses the company’s MotionSync™ technology to deliver uniform exfoliation
- AMI Pharm Advances AYP-101 to Phase 3 Testing for Noninflammatory Fat Reductionhttps://modernaesthetics.com/news/ami-pharm-advances-ayp-101-to-phase-3-testing-for-noninflammatory-fat-reduction/2476093/AMI Pharm has initiated a pivotal Phase 3 clinical trial of AYP-101, an investigational injectable for the treatment of submental fat. The study will evaluate the efficacy and safety of the agent, which is designed to reduce localized fat with fewer inflammatory side effects than current therapie
- SkinCeuticals Introduces A.G.E. Interrupter Ultra Serum to Address Sagging Skinhttps://modernaesthetics.com/news/skinceuticals-introduces-age-interrupter-ultra-serum-to-address-sagging-skin/2476036/SkinCeuticals announced the launch of its A.G.E. Interrupter Ultra Serum, a new addition to its A.G.E. line designed to target skin laxity. Sagging skin, often heightened by factors such as rapid weight loss, has become a growing concern among patients seeking dermatologic care. This serum offers
- Merz Aesthetics Names New US Sales and Marketing Leadershttps://modernaesthetics.com/news/merz-aesthetics-names-new-us-sales-and-marketing-leaders/2475952/Merz Aesthetics has appointed Chris Van Dyk as Vice President of US Sales and DJ Sethares as Vice President of US Marketing, the company announced. Both executives will lead commercial functions across the US to support growth of the company’s aesthetics portfolio. Van Dyk previously serve
- Report: GLP-1s Dethrone Skincare Shifting Medical Aesthetic Spendhttps://modernaesthetics.com/news/report-glp-1s-dethrone-skincare-shifting-medical-aesthetic-spend/2475902/Weight-loss medications continue to impact the medical aesthetics industry. GLP-1s surpassed skincare as the top consumer spend category, according to a new report from Guidepoint Qsight. Guidepoint Qsight found patients are focusing on the overall wellness journey, prioritizing bundling
- Alma Launches AI-Assisted Skincare System with Nearly 12M Formulation Optionshttps://modernaesthetics.com/news/alma-launches-ai-assisted-skincare-system-with-nearly-12m-formulation-options/2475858/Alma has launched Universkin by Alma, a new AI-assisted medical-grade skincare platform designed to support physicians in offering personalized treatment regimens. The system enables rapid clinical assessment and tailored formulation of topical therapies using an intelligent diagnostic algorithm
- Obagi Medical Acquires Novaestiq to Introduce HA Injectables in US Markethttps://modernaesthetics.com/news/obagi-medical-acquires-novaestiq-to-introduce-ha-injectables-in-us-market/2475814/Obagi Medical is set to expand into aesthetic injectables following the acquisition of Novaestiq Corp., the company behind the Saypha® ChIQ™ and Saypha® MagIQ™ hyaluronic acid (HA) filler products. The transaction was completed by Obagi’s parent company, Waldencast
- Global Botulinum Toxins Market Projected to Reach $15.7 Billion by 2030https://modernaesthetics.com/news/global-botulinum-toxins-market-projected-to-reach-157-billion-by-2030/2475785/The global market for botulinum toxin products is expected to grow from $8.9 billion in 2025 to $15.7 billion by 2030, according to new projections from MarketsandMarkets, representing a compound annual growth rate (CAGR) of 11.7%. This sustained growth is attributed to increased global de